Business
Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries
Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n Study Carried Out by Center for Research and Advanced Studies of the IPN and the Siglo XXI National Medical Center Show Advantages of Oral Administration of CBD to Reduce Levels of Neuronal Death in Animal Model SAN DIEGO, CA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary HempMeds® recently took part in a collaboration on a study to demonstrate the effectiveness of hemp-based cannabidiol (CBD) in the treatment of Parkinson's Disease.  The Company is also collaborating with the Center for Research and Advanced Studies of Neurological Diseases at the Siglo XXI National Medical Center, on a preclinical study in an animal model that demonstrated the ability to decrease extracellular glutamate levels that can lead to traumatic brain injuries. This innovative study, which was led by Dr. Luisa Rocha in conjunction with a large group of Mexican scientists, demonstrated the efficacy of oral administration of the Company’s proprietary RSHO CBD product in the treatment of traumatic brain injuries, generated by a reduction in the excessive release of glutamate in the cerebral cortex. “Through this controlled study, we were able to observe that the oral administration of cannabidiol during the seven days prior to an injury helped to avoid the over-release of glutamate that results from brain trauma, an effect associated with decreased mortality in neurons. In this study, it was also shown that the application of CBD helps sensorimotor improvement,” Dr. Rocha stated. Glutamate is the main excitatory neurotransmitter of the central nervous system.  Abnormally high levels of glutamate lead to a process called excitotoxicity, which can lead to death of neurons. Dr. Rocha added: “The results obtained in this study help to understand how the oral application of cannabidiol reduces excitotoxicity caused by long-term traumatic brain injuries and facilitates functional recovery. In fact, pre-injury CBD treatment was sufficient to lessen the aftermath of traumatic brain injury.” “Clinically proving t...